Fennec PharmaceuticalsFENC +4.45%54 Days Payable is 873.76 as of Mar. 2026, which is 36% above its 10-year median of 644.13. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $9.94 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Fennec Pharmaceuticals ranks better than 79.35% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fennec Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fennec Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fennec Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fennec Pharmaceuticals (FENC) has a Days Payable of 873.76 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fennec Pharmaceuticals and its competitors. This is 36% above median its historical median of 644.13. Over the past decade, Fennec Pharmaceuticals' Days Payable has ranged from 386.96 to 6,616.79. According to the industry distribution chart, Fennec Pharmaceuticals ranks #146 out of 707 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Fennec Pharmaceuticals' Days Payable too high?
Fennec Pharmaceuticals' current Days Payable of 873.76 is 36% above median its 10-year median of 644.13. Over the past 10 years, this metric has ranged from a low of 386.96 to a high of 6,616.79. The Biotechnology industry median Days Payable is 113.76. Fennec Pharmaceuticals' value of 873.76 is 668.1% above this industry median. Based on the distribution chart, Fennec Pharmaceuticals ranks #146 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fennec Pharmaceuticals ranks #146 out of 707 companies for Days Payable. This places Fennec Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Fennec Pharmaceuticals' value of 873.76 is 668.1% above this benchmark. Historically, Fennec Pharmaceuticals' own Days Payable has ranged from 386.96 to 6,616.79 over the past decade. While the company's 10-year median is 644.13 vs. the industry median of 113.76, Fennec Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fennec Pharmaceuticals's current Days Payable of 873.76 is 668.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fennec Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fennec Pharmaceuticals's current Days Payable is 873.76, which is 36% above median its own 10-year median of 644.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Modestly Overvalued. The stock's GF Value™ is $9.94, compared to a current price of $11.02 — trading 10.9% above its estimated fair value. The current Days Payable is 873.76, which is 36% above median its 10-year median of 644.13 and 668.1% above the Biotechnology industry median of 113.76. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Days Payable is 873.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?
Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued.
The current stock price of $11.02 is trading 10.9% above its estimated GF Value™ of $9.94.
GuruFocus considers Fennec Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for FENC:
Days Payable: 873.76 (36% above median its 10-year median of 644.13)
GF Value™: $9.94 vs. price of $11.02 (10.9% above fair value)
Industry Position: 668.1% above the Biotechnology median (#146 of 707)
No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score
Get the complete analysis for FENC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FENC has been successfully added to your 
